English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Summary The aim of the study was to evaluate seizure liability in rats against the convulsant pentylenetetrazole (PTZ) during a 14-day treatment with retigabine (RTG). The seizure liability was also studied on the 1 st , 2 nd  and 3 rd  day after the abrupt determination of its administration. Male Wistar rats were divided in groups of 10 and treated orally for 14 days (1 st  – 6 th  group with distilled water, and 7 th  – 12 th  group with retigabine (RTG) at a dose of 60 mg/kg bw The tolerance to the anticonvulsant effect of RTG was studied using subcutaneous injection of PTZ (120 mg/kg bw) on the 1 th  and 14 th  day. To determine the possible neuronal hyperexcitability on the 1 st , 2 nd  and 3 rd  day after termination of drug administration, a lower dose of PTZ (65 mg/kg bw) was used. According to our results there was no change in the anticonvulsant activity of RTG during the whole period of treatment. The study on withdrawal syndrome showed slightly decrease of the effect on the first day after the last treatment, but with no significant difference to the controls. The anticonvulsant effect of RTG on the 2 nd  and 3 rd  day was close to that in the control group. Our results showed no development of tolerance on subchronic treatment with RTG. There was no significant change in the neuronal hyperexcitability on the 1 st , 2 nd  and 3 rd  day after the termination of treatment. Based on these results we can suggest that RTG has no potential to develop withdrawal syndrome.

Experimental Study On The Development Of Tolerance And Withdrawal Syndrome To Pentylenetetrazole-Induced Seizures In Rats Treated With Retigabine